Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine.
about
Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining IssuesClinical utility of imaging for evaluation of hepatocellular carcinomaRecent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRIUpdate in management of hepatocellular carcinoma in Eastern populationRecent advances in the imaging of hepatocellular carcinomaDiagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitisUltrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging featuresCharacterization of incidental liver lesions: comparison of multidetector CT versus Gd-EOB-DTPA-enhanced MR imagingGadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysisAPASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.Gadoxetic acid-enhanced MRI for T-staging of gallbladder carcinoma: emphasis on liver invasion.Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma.Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma (HCC): A Comparative Study with Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced Computed Tomography (CT).Gadoxetic acid-enhanced fat suppressed three-dimensional T1-weighted MRI using a multiecho dixon technique at 3 tesla: emphasis on image quality and hepatocellular carcinoma detection.Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.Consensus report from the 6th International forum for liver MRI using gadoxetic acid.Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.Gadoxetic acid: pearls and pitfalls.Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.Assessment of clinical and magnetic resonance imaging features of de novo hypervascular hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T.Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.Enhancement of liver and pancreas on late hepatic arterial phase imaging: quantitative comparison among multiple gadolinium-based contrast agents at 1.5 Tesla MRI.Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis.Experimental studies on artifacts and tumor enhancement on gadoxetic acid-enhanced arterial phase liver MRI in a rabbit VX2 tumor model.Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.Diagnosis of focal liver lesions with gadoxetic acid-enhanced MRI: is a shortened delay time possible by adding diffusion-weighted imaging?Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteriaHepatocellular carcinoma in a North American population: Does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?
P2860
Q26770020-22FF1073-DDA1-46DB-B152-C6D2E51094EEQ26823224-B21F0B8C-9B29-4431-BCC5-B015C77A4CF0Q28075361-865D17A1-EDD5-4078-B29A-44DA7DDBA901Q28080480-BB027A74-A4D5-468A-9385-B7631E910F00Q30415186-2D81083A-C2BE-4431-9A52-222392C76CBCQ33652009-9946CD91-BCEF-46CA-9B84-52E15C8ACB4EQ34115828-CAB985BA-B5F8-4A37-875F-E64F4187D664Q34682228-7226B60B-9825-47C9-84D7-1DB677D9CE5BQ34776353-C4715530-F0F5-4839-A267-7DF1757E434CQ34963150-4147DFAB-F3E5-49B5-8D73-D94CC16437F7Q35207736-0F8594AF-3C72-4A75-A4BB-1ABBF39B2C4CQ36343921-02DEFAE2-D3A8-471E-A286-AAF67B151E1CQ37487034-DFB50744-4BBC-4E2B-87D1-989D8558B6C6Q37504877-B1292728-AC01-44A0-8466-A1034E26A79AQ37605822-DA80C372-8149-4C7C-A101-CBE4440FA921Q37631122-390295B3-1236-42C2-A366-21C8D8210959Q37635549-22E39777-525D-4816-A22D-21383486ADD4Q38071993-528AAC42-E2A1-4757-BE1E-9FE0F058DD8CQ38083429-0F54FD93-9E6F-48CD-8E2B-AC94BCDB335FQ38219801-7D6E8C34-28DB-4DFF-86D1-F54664C1F002Q38238010-F386C3BC-5BD6-4607-96C2-DD4B86922E51Q38329089-61A81CF3-51ED-469A-B2DB-D6AD2790CD5FQ38399641-EEBA8A8B-9269-4C7B-83A7-F88F4807A107Q38434362-87139202-96B8-465D-9686-CF17C93341FEQ38830332-7F1A51FA-2140-4B07-9745-A9BD395CCB2DQ38838743-0D33D1EC-7090-40E4-8CFD-670F1B48C547Q40072345-7D66C6C8-07B5-4EBF-84E8-C326338C2DA6Q41962614-B060D6C4-C681-484E-9027-41298DD75117Q42007162-57F04B6E-B49B-4417-BBEA-287914E2BA74Q44126425-64F73201-469F-43EE-8BAA-2AE707EBCFEDQ45797802-BC1D5D97-D4B8-4239-A3AA-ACAFB2507C94Q46194736-1D3906C3-815A-4979-B6DB-D666BEEC85CBQ47681929-C8EBB6FC-9611-40CE-9C28-2639F2DCFB2FQ53109359-FF54652A-90FF-4A89-B990-979E60FD73D8Q53127886-5359CC87-8837-40B3-9612-91CAF903230EQ53151193-1D00FF1A-44A6-487A-B31C-70FEC3E0C0F5Q53525275-B6499B9A-5095-45E5-8742-D71250116929Q57911034-2647E732-E510-42C3-B451-EA69A6F384D5
P2860
Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@ast
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@en
type
label
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@ast
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@en
prefLabel
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@ast
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@en
P2093
P2860
P356
P1476
Diagnostic efficacy of gadoxet ...... ith gadopentetate dimeglumine.
@en
P2093
P2860
P304
P356
10.1259/BJR/66686028
P407
P577
2010-08-03T00:00:00Z